- Home
- IGC vs LTRN Comparison
IGC vs LTRN Comparison
Compare IGC & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IGC | LTRN |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 27.6M |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IGC | LTRN |
|---|---|---|
| Price | $0.29 | $1.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 129.4K |
| Earning Date | 03-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.09 | 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,271,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $1.11 |
| 52 Week High | $0.45 | $4.70 |
Technical Indicators
Market Signals| Indicator | IGC | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 23.88 |
| Support Level | $0.28 | $1.11 |
| Resistance Level | $0.31 | $2.41 |
| Average True Range (ATR) | 0.01 | 0.20 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 26.32 | 5.88 |
Price Performance
Historical ComparisonAbout IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.